Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Temozolomide-polymer local slow release chemotherapy medicine for treating malignant brain tumor

A malignant brain tumor, temozolomide technology, applied in the medical field, can solve the problem of short residence time of brain tumor tissue

Inactive Publication Date: 2005-05-18
赵世光 +1
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Oral absorption of temozolomide can pass through the blood-brain barrier and enter the cerebrospinal fluid, but it has been reported in the literature that its drug concentration in the cerebrospinal fluid is only 30-40% of the plasma, and the brain tumor tissue has a short residence time, causing side effects such as bone marrow suppression and gastrointestinal reactions.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0008] The present invention is composed of temozolomide and macromolecular biodegradable polymer material, adopts the composite method of polymer medicament, and makes tablets with different thicknesses and shapes through molding or casting technology, and each tablet contains temozolomide to control the biological characteristics of different tumors. In the range of 5-20mg, it is sterilized by γ-ray irradiation after it is made.

[0009] The invention integrates the temozolomide with anti-tumor effect into the degradable polymer macromolecule, and releases the drug slowly, continuously and stably through the erosion and hydrolysis of the polymer and exerts its effect. High molecular polymers are biodegradable materials, and their own metabolites are non-toxic, and have the advantages of high drug loading rate, good biocompatibility and small antigenicity. There are many kinds of biodegradable polymer materials that can be selected: such as polylactic acid (PLA), polyglycolic...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses a slow release system of Temozolomide as local slow release medicine and biodegraded polymer for treating malignant brain tumor, and the slow release system is implanted into operated area of excising malignant brain tumor for local slow release treatment of malignant brain tumor and prolonging the survival period of the patient. The present invention consists of Temozolomide and biodegraded polymer material in the weight ratio of 1.5 to 10. Temozolomide is fused into biodegraded polymer, and through the corrosion of the polymer and hydrolysis of the polymer, the medicine is released slowly, continuously and stably to act. The polymer is PLA, PGA, PLGA, PFAD-SA and / or the copolymer of p-carboxyl phenoxyl propane and sebasic acid.

Description

Technical field: [0001] The invention belongs to a local slow-release drug, in particular to a local slow-release chemotherapeutic drug for treating malignant brain tumors. The invention is a new dosage form of the chemotherapeutic drug temozolomide except the oral dosage form, which broadens its application range and belongs to the field of medical technology. technical background: [0002] Temozolomide is a new type of chemotherapy drug for oral treatment of glioma. It belongs to imidazolium tetrazine derivatives. It was approved for marketing by the European Union and the United States in 1999. It is a second-line drug for glioblastoma such as astrocytoma, and the approved indications in EU countries are glioblastoma multiforme that still develops or recurs after conventional treatment. Glioma accounts for the first place in central nervous system tumors and is one of the refractory diseases in neurosurgery. Due to the infiltrative growth of glioma and the unclear bound...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61K31/4188A61P35/00
Inventor 赵世光张健
Owner 赵世光
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com